EUVIMEDScopri EUVIMED
Übersichtsarbeit

Reassessing PCI Timing in High Bleeding Risk Patients: Evidence, Strategies, and Outcomes

Ameer Awashra iD, Mohammed AbuBaha iD, Ahmed Emara iD, Ahmad Hamdan iD, Anwar Zahran iD, Mazen Ibrahem iD, Nadeem Khayat, Mohamed S Elgendy iD, Ahmad Nouri iD, Mohamed Saad Rakab, Atef Akoum, Abdalhakim Shubietah iD

Catheterization and Cardiovascular Interventions · 2026

DOI: 10.1002/ccd.70410 ↗

At a glance

Übersichtsarbeit in Catheterization and Cardiovascular Interventions, 2026. Written by Ameer Awashra and 11 co-authors. Institution: Department of Medicine, An Najah National University, Nablus, Palestine. Major MEDLINE topics: Hemorrhage, Percutaneous Coronary Intervention, Time-to-Treatment, Platelet Aggregation Inhibitors. Cited 4 times so far (Crossref); 99 references. Funded by: The authors received no specific funding for this work..

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Percutaneous coronary intervention (PCI) in patients with high bleeding risk (HBR) presents a therapeutic challenge, requiring careful balancing of ischemic prevention and bleeding avoidance. The Academic Research Consortium High Bleeding Risk (ARC‐HBR) criteria provide a standardized framework for identifying this population, yet optimal PCI timing, procedural strategies, and antithrombotic regimens remain uncertain. This review synthesizes data from randomized controlled trials, large‐scale registries, and meta‐analyses involving HBR patients undergoing PCI in settings including stable coronary artery disease, acute coronary syndromes (ACS), ST‐elevation myocardial infarction (STEMI), post‐resuscitation states, and malignancy‐related thrombocytopenia. Special emphasis is placed on procedural approaches (radial vs. femoral access), device selection (drug‐coated balloons, polymer‐free drug‐eluting stents), and dual antiplatelet therapy (DAPT) duration. Evidence supports the safety of abbreviated DAPT regimens (1–3 months) when combined with bleeding‐sparing techniques and devices, with the greatest benefit observed in patients with a high ischemic burden (e.g., GRACE score > 140). Early invasive management in ACS has been associated with reduced ischemic endpoints and shorter hospital stays without a significant rise in major bleeding. Conversely, delayed PCI is advisable in the presence of active bleeding, recent thrombolysis, or severe coagulopathy. Persistent limitations include underrepresentation of ARC‐HBR patients in trials and lack of standardized, bleeding risk–tailored timing protocols. PCI in HBR patients can be performed safely and effectively when guided by individualized, evidence‐based strategies for procedural timing and antithrombotic therapy. Future directions include integrating biomarker‐driven DAPT modulation and artificial intelligence‐based decision frameworks to optimize outcomes in this high‐risk group.

Subjects

MeSH terms (MEDLINE)

HemorrhagePercutaneous Coronary InterventionTime-to-TreatmentPlatelet Aggregation InhibitorsCoronary Artery DiseaseFibrinolytic AgentsHumansRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeClinical Decision-Making

Author keywords

PCIacute coronary syndromeshigh bleeding riskpercutaneous coronary intervention

Substances

Platelet Aggregation InhibitorsFibrinolytic Agents

Authors and institutions

  • Department of Medicine, An Najah National University, Nablus, Palestine.
  • Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
  • College of Medicine, QU Health, Qatar University, Doha, Qatar.
  • Faculty of Medicine, Mansoura University, Mansoura, Egypt.
  • Faculty of Medicine, Tanta University, Tanta, Gharbia, Egypt.
  • Department of Medicine, Hennepin Healthcare, Minneapolis, Minnesota, USA.

ORCID profiles: Ameer Awashra, Mohammed AbuBaha, Ahmed Emara, Ahmad Hamdan, Anwar Zahran, Mazen Ibrahem, Mohamed S Elgendy, Ahmad Nouri, Abdalhakim Shubietah

Funding

  • The authors received no specific funding for this work.

Cite

APA

Awashra, A., AbuBaha, M., Emara, A., Hamdan, A., Zahran, A., Ibrahem, M., Khayat, N., Elgendy, M. S., Nouri, A., Rakab, M. S., Akoum, A., & Shubietah, A. (2026). Reassessing PCI Timing in High Bleeding Risk Patients: Evidence, Strategies, and Outcomes. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.70410

Vancouver

Awashra A, AbuBaha M, Emara A, Hamdan A, Zahran A, Ibrahem M, et al. Reassessing PCI Timing in High Bleeding Risk Patients: Evidence, Strategies, and Outcomes. Catheterization and Cardiovascular Interventions. 2026. doi:10.1002/ccd.70410

BibTeX
@article{Awashra2026,
  author = {Awashra, Ameer and AbuBaha, Mohammed and Emara, Ahmed and Hamdan, Ahmad and Zahran, Anwar and Ibrahem, Mazen and Khayat, Nadeem and Elgendy, Mohamed S and Nouri, Ahmad and Rakab, Mohamed Saad and Akoum, Atef and Shubietah, Abdalhakim},
  title = {Reassessing PCI Timing in High Bleeding Risk Patients: Evidence, Strategies, and Outcomes},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2026},
  doi = {10.1002/ccd.70410}
}
Start for free →